Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

AVEO Pharmaceuticals

DB:VPA
Snowflake Description

High growth potential and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VPA
DB
$56M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. The last earnings update was 20 days ago. More info.


Add to Portfolio Compare Print
  • AVEO Pharmaceuticals has significant price volatility in the past 3 months.
VPA Share Price and Events
7 Day Returns
-15.9%
DB:VPA
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-59.8%
DB:VPA
-13.2%
DE Biotechs
-20.9%
DE Market
VPA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AVEO Pharmaceuticals (VPA) -15.9% -16.5% -39.3% -59.8% -39.1% -77.1%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • VPA underperformed the Biotechs industry which returned -13.2% over the past year.
  • VPA underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
VPA
Industry
5yr Volatility vs Market

Value

 Is AVEO Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for AVEO Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €3.32.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AVEO Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AVEO Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:VPA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $0.61
NasdaqCM:AVEO Share Price ** NasdaqCM (2020-04-03) in USD $3.47
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AVEO Pharmaceuticals.

DB:VPA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:AVEO Share Price ÷ EPS (both in USD)

= 3.47 ÷ 0.61

5.67x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AVEO Pharmaceuticals is good value based on earnings compared to the Europe Biotechs industry average.
  • AVEO Pharmaceuticals is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does AVEO Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:VPA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 5.67x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
24.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

DB:VPA PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 5.67x ÷ 24.6%

0.23x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AVEO Pharmaceuticals is good value based on expected growth next year.
Price based on value of assets
What value do investors place on AVEO Pharmaceuticals's assets?
Raw Data
DB:VPA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.92
NasdaqCM:AVEO Share Price * NasdaqCM (2020-04-03) in USD $3.47
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:VPA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:AVEO Share Price ÷ Book Value per Share (both in USD)

= 3.47 ÷ 0.92

3.76x

* Primary Listing of AVEO Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AVEO Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess AVEO Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. AVEO Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is AVEO Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
24.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is AVEO Pharmaceuticals expected to grow at an attractive rate?
  • AVEO Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • AVEO Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • AVEO Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:VPA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:VPA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 24.6%
DB:VPA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 39.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:VPA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:VPA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 111 3 2
2023-12-31 121 31 2
2022-12-31 34 -27 2
2021-12-31 15 -35 3
2020-12-31 8 -33 3
2020-04-05
DB:VPA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 29 -3 9
2019-09-30 30 -2 36
2019-06-30 6 -24 -3
2019-03-31 6 -27 4
2018-12-31 5 -25 -5
2018-09-30 4 -22 -24
2018-06-30 6 -22 -28
2018-03-31 6 -20 -65
2017-12-31 8 -19 -65
2017-09-30 8 -23 -74
2017-06-30 4 -29 -53
2017-03-31 4 -26 -28

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • AVEO Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • AVEO Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:VPA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from AVEO Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:VPA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.09 0.11 0.07 2.00
2023-12-31 0.80 1.17 0.42 2.00
2022-12-31 -0.74 -0.42 -1.05 2.00
2021-12-31 -1.55 -0.90 -2.47 3.00
2020-12-31 -1.80 -1.68 -2.04 3.00
2020-04-05
DB:VPA Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 0.61
2019-09-30 2.47
2019-06-30 -0.22
2019-03-31 0.34
2018-12-31 -0.44
2018-09-30 -1.99
2018-06-30 -2.35
2018-03-31 -5.59
2017-12-31 -6.14
2017-09-30 -7.78
2017-06-30 -6.22
2017-03-31 -3.80

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if AVEO Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess AVEO Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AVEO Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has AVEO Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AVEO Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AVEO Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.
  • AVEO Pharmaceuticals has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • AVEO Pharmaceuticals has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
AVEO Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AVEO Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:VPA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 28.80 9.39 11.21
2019-09-30 29.51 35.67 10.95
2019-06-30 6.26 -2.93 10.79
2019-03-31 5.99 4.21 10.63
2018-12-31 5.41 -5.33 10.78
2018-09-30 4.01 -23.65 10.56
2018-06-30 6.16 -27.88 9.94
2018-03-31 6.07 -65.17 9.42
2017-12-31 7.58 -65.03 9.14
2017-09-30 7.62 -74.13 8.60
2017-06-30 4.00 -52.70 8.64
2017-03-31 3.84 -28.02 8.07
2016-12-31 2.52 -26.89 8.21
2016-09-30 5.99 -27.87 9.99
2016-06-30 20.15 -14.99 10.08
2016-03-31 20.09 -11.84 11.23
2015-12-31 19.02 -15.00 10.22
2015-09-30 15.54 -22.31 10.57
2015-06-30 1.26 -44.66 13.43
2015-03-31 2.97 -57.16 15.39
2014-12-31 18.12 -52.74 18.59
2014-09-30 18.33 -55.57 19.98
2014-06-30 17.78 -65.44 19.34
2014-03-31 16.26 -79.39 21.82
2013-12-31 1.29 -107.03 28.71
2013-09-30 16.50 -111.78 33.68
2013-06-30 17.20 -117.60 38.54

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Whilst AVEO Pharmaceuticals made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%), this is metric is skewed due to its high level of debt.
  • AVEO Pharmaceuticals used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • It is difficult to establish if AVEO Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess AVEO Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AVEO Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is AVEO Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AVEO Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AVEO Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • AVEO Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of AVEO Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AVEO Pharmaceuticals Company Filings, last reported 3 months ago.

DB:VPA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 14.85 15.77 47.75
2019-09-30 18.76 17.97 57.65
2019-06-30 1.63 19.34 40.23
2019-03-31 -18.58 19.20 23.48
2018-12-31 -27.23 19.03 24.43
2018-09-30 -60.39 18.88 20.41
2018-06-30 -45.45 18.73 18.09
2018-03-31 -50.25 18.59 27.00
2017-12-31 -40.76 18.48 33.53
2017-09-30 -44.57 19.24 37.41
2017-06-30 -19.33 19.12 40.13
2017-03-31 4.91 14.14 33.41
2016-12-31 -1.92 14.00 23.35
2016-09-30 3.54 13.87 30.83
2016-06-30 8.29 13.74 39.53
2016-03-31 9.92 9.56 23.81
2015-12-31 17.23 9.47 34.14
2015-09-30 23.88 12.48 37.24
2015-06-30 11.24 15.30 26.77
2015-03-31 14.59 18.02 39.07
2014-12-31 20.61 20.65 52.31
2014-09-30 34.27 20.45 63.39
2014-06-30 46.96 14.18 64.94
2014-03-31 64.27 16.73 88.32
2013-12-31 69.94 19.21 118.51
2013-09-30 85.81 21.59 130.36
2013-06-30 108.91 23.89 156.17
  • AVEO Pharmaceuticals's level of debt (106.2%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (100.4% vs 106.2% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on AVEO Pharmaceuticals's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess AVEO Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AVEO Pharmaceuticals has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is AVEO Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from AVEO Pharmaceuticals dividends.
If you bought €2,000 of AVEO Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate AVEO Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate AVEO Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:VPA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:VPA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as AVEO Pharmaceuticals has not reported any payouts.
  • Unable to verify if AVEO Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of AVEO Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as AVEO Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess AVEO Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AVEO Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AVEO Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of AVEO Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Bailey
COMPENSATION $3,110,562
AGE 54
TENURE AS CEO 5.3 years
CEO Bio

Mr. Michael P. Bailey has been Chief Executive Officer and President of AVEO Pharmaceuticals, Inc. since January 7, 2015 and served as its Secretary. Mr. Bailey served as the Principal Financial Officer of AVEO Pharmaceuticals, Inc. from September 26, 2019 to January 2020. He served as the Principal Financial Officer of AVEO Pharmaceuticals, Inc. until April 2015. He served as Chief Business Officer of AVEO Pharmaceuticals, Inc. since June 2013 and as its Chief Commercial Officer from September 2010 to June 2013. He served as the Chief Commercial Officer and Senior Vice President, Business Development of Synta Pharmaceuticals Corp. from August 4, 2008 to September 7, 2010. He served as Senior Vice President of Commercial Operations at ImClone Systems Corporation from August 2, 2006 to August 1, 2008 and Vice President of Marketing since January 2003. Mr. Bailey has executive and operational experience in the pharmaceutical and biotech industries, with nearly a decade dedicated to oncology. Since 1999, he held leadership positions of increasing responsibility at ImClone Systems Incorporated. He led ImClone's Worldwide Commercial Organization, responsible for commercial aspects for the planning and launch of Erbitux(R) across multiple indications. He served at Genentech, Inc. from 1997 to 1999 where he managed its cardiovascular development portfolio. He serves as a Director of AVEO Pharmaceuticals, Inc. since January 2015. He started his career in the pharmaceutical industry as one of two MBA graduates selected for Smith-Kline Beecham's Executive Marketing Development Program, where he held a variety of commercial roles, including sales, strategic planning and product management from 1992 to 1997. Mr. Bailey earned a BS in Psychology and also his MBA in International Marketing by graduating with honors from both St. Lawrence University and the University of Notre Dame Graduate School of Business.

CEO Compensation
  • Michael's compensation has increased in line with AVEO Pharmaceuticals recently becoming profitable.
  • Michael's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the AVEO Pharmaceuticals management team in years:

4.3
Average Tenure
52
Average Age
  • The tenure for the AVEO Pharmaceuticals management team is about average.
Management Team

Michael Bailey

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
54
TENURE
5.3 yrs

Karuna Rubin

TITLE
Senior VP & General Counsel
COMPENSATION
$1M
AGE
42
TENURE
4.8 yrs

Mike Needle

TITLE
Chief Medical Officer
COMPENSATION
$1M
AGE
59
TENURE
5.3 yrs

Erick Lucera

TITLE
Chief Financial Officer
AGE
51
TENURE
0.3 yrs

Lisa Bruneau

TITLE
VP of Financial Accounting & Reporting and Treasurer
AGE
52
TENURE
4.3 yrs

Emile Farhan

TITLE
Senior Vice President of Technical Operations & Quality Assurance

Kevin Peacock

TITLE
Vice President of Marketing
TENURE
0.4 yrs

Mike Ferraresso

TITLE
Senior Vice President of Business Analytics & Commercial Operations

Darlene Noci

TITLE
Interim Head of Regulatory Affairs
TENURE
0.5 yrs
Board of Directors Tenure

Average tenure and age of the AVEO Pharmaceuticals board of directors in years:

10.8
Average Tenure
70
Average Age
  • The average tenure for the AVEO Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Michael Bailey

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
54
TENURE
5.3 yrs

Tony Evnin

TITLE
Independent Director
COMPENSATION
$102K
AGE
78
TENURE
18.1 yrs

Ken Bate

TITLE
Lead Outside Director
COMPENSATION
$125K
AGE
69

Robert Young

TITLE
Independent Director
COMPENSATION
$95K
AGE
79
TENURE
10.8 yrs

Raju Kucherlapati

TITLE
Member of Scientific Advisory Board
COMPENSATION
$3K
AGE
76

Tyler Jacks

TITLE
Member of Scientific Advisory Board
AGE
58

H. Horvitz

TITLE
Member of Scientific Advisory Board

Lynda Chin

TITLE
Member of Scientific Advisory Board

Lewis Cantley

TITLE
Member of Scientific Advisory Board
AGE
70

Douglas Hanahan

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
25. Nov 19 Buy Michael Bailey Individual 21. Nov 19 21. Nov 19 15,000 €5.40 €80,958
08. Apr 19 Buy New Enterprise Associates, Inc. Company 08. Apr 19 08. Apr 19 434,783 €10.12 €4,401,888
X
Management checks
We assess AVEO Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AVEO Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody for the treatment of squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company’s preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent’s Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. AVEO Pharmaceuticals, Inc. has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

Details
Name: AVEO Pharmaceuticals, Inc.
VPA
Exchange: DB
Founded: 2001
$51,720,776
16,080,616
Website: http://www.aveooncology.com
Address: AVEO Pharmaceuticals, Inc.
One Broadway,
14th Floor,
Cambridge,
Massachusetts, 02142,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM AVEO Common Stock Nasdaq Capital Market US USD 12. Mar 2010
DB VPA Common Stock Deutsche Boerse AG DE EUR 12. Mar 2010
BRSE VPA Common Stock Berne Stock Exchange CH CHF 12. Mar 2010
Number of employees
Current staff
Staff numbers
19
AVEO Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 22:18
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/01
Last earnings filing: 2020/03/16
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.